HNGEHealthcare · Health Information ServicesThe 16 Wall Street analysts covering Hinge Health, Inc. hold a median 12-month price target of $105 — +16.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Hinge Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HNGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.7% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Truist Securities | Maintains | Buy | $85 → $112 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | $97 → $100 |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | $96 → $107 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $100 → $105 |
| 5 Aug 2026 | Needham | Maintains | Buy | $76 → $97 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $75 → $110 |
| 5 Aug 2026 | Wells Fargo | Maintains | Overweight | $90 → $103 |
| 27 July 2026 | Citizens | Maintains | Market Outperform | — |
| 27 July 2026 | Citizens | Maintains | Market Outperform | $80 → $96 |
| 27 July 2026 | Stifel | Maintains | Buy | $79 → $90 |
| 27 July 2026 | Stifel | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $76 → $100 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 July 2026 | Barclays | Maintains | Overweight | — |
| 13 July 2026 | Barclays | Maintains | Overweight | $70 → $97 |
| 13 July 2026 | Keybanc | Maintains | Overweight | $90 → $125 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Morgan Stanley | Maintains | Overweight | $72 → $108 |
| 13 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 24 June 2026 | Wells Fargo | Maintains | Overweight | $80 → $90 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HNGE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Hinge Health, Inc. returned +56.3% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 15% of US stocks
Cheaper than 5% of US stocks
Cheaper than 3% of US stocks
Higher than 87% of US stocks
Higher than 76% of US stocks
Higher than 95% of US stocks
Higher than 78% of US stocks
Higher than 78% of US stocks
Higher than 88% of US stocks
Higher than 87% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Hinge Health, Inc. has a market value of $7.3B and an enterprise value of $6.8B.
Revenue in the twelve months to 30 June 2026: $720.1M. The latest quarter grew 53.0% year on year.
Net income over the same four quarters: $109.1M, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $1.28.
Free cash flow in the twelve months to 30 June 2026: $283.9M, after $6.2M of capital spending.
Trailing P/E: 10.8×; forward P/E: 28.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Hinge Health, Inc. employs 1,437 people — $501K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Hinge Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Hinge Health's stock has found support at a key level in recent weeks and is approaching multiple new buy points despite broader market weakness, according to Investor's Business Daily.
Why it matters — A HNGE watcher would care because the stock's technical positioning at key support and near potential buy points signals a notable shift in its chart pattern.
MarketBeat discusses Hinge Health's strategy of using a single platform to address multiple, seemingly unrelated ailments. The article notes that while individual symptoms are often connected, typical care requires separate visits to different specialists, contrasting with Hinge Health's integrated approach.
Why it matters — A HNGE watcher would care because Hinge Health's expansion from a single condition to a broad, multi-ailment platform is central to its business strategy and value proposition.
Hinge Health's stock has surged nearly 90% year-to-date, supported by 53% revenue growth, wider margins, and expansion into migraine and gastrointestinal care, though the article notes execution risks remain.
Why it matters — The report highlights both the company's strong momentum and the remaining execution risks that HNGE watchers should track.
Zacks Investment Research notes that Hinge Health (HNGE) maintains growth prospects through strong revenue growth, a raised 2026 outlook, and expansion into Migraine and GI care, despite pressures from investments.
Why it matters — This item highlights factors supporting HNGE's growth prospects, which would be of interest to those tracking the company's performance outlook.
Zacks Research reports that Hinge Health's rapid revenue growth, widening margins, and increased 2026 outlook strengthen its investment case, though the company's expansion also raises execution risks.
Why it matters — A Hinge Health watcher would care because the report highlights accelerating growth and improved profitability as positive drivers, while flagging execution risks tied to the company's expansion.
The 16 Wall Street analysts covering Hinge Health, Inc. have a median 12-month price target of $105, with estimates ranging from $85 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Hinge Health, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hinge Health, Inc. 82 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Hinge Health, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +16.7% from the last close, and Ticker Nerd's factor model ranks Hinge Health, Inc. 82 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Hinge Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HNGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $140 over the next 12 months.
Hinge Health, Inc. returned +56.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Hinge Health Inc. is a digital health company specializing in software and wearable technology designed to improve joint and muscle health.
The most recent item we track (Investors Business Daily, 21 Aug 2026): "IPO Stock Of The Week: Hinge Health Finds Support At Key Level, Eyes New Buy Points". Hinge Health's stock has found support at a key level in recent weeks and is approaching multiple new buy points despite broader market weakness, according to Investor's Business Daily.
Hinge Health Inc. is a digital health company specializing in software and wearable technology designed to improve joint and muscle health. The company's primary platform delivers digital exercise therapy programs, enabling users to proactively manage musculoskeletal conditions, acute injuries, chronic pain, and post-surgical rehabilitation. By integrating digital care pathways and connected devices, Hinge Health empowers patients to access evidence-based therapy remotely, reducing barriers associated with traditional in-person care. Founded in 2012 and headquartered in San Francisco, Hinge Health serves a diverse client base, including employers and health plans, seeking to lower healthcare costs and improve outcomes for members with musculoskeletal needs. The company’s solutions span clinical support, personalized exercise regimens, and tracking tools, providing a comprehensive approach to care. With strong revenue growth and a focus on innovation in digital therapeutics, Hinge Health plays a significant role in the evolving landscape of healthcare technology and value-based care models.
CEO Mr. Daniel A. Perez · 1,437 employees · United States · https://www.hingehealth.com
